Savara to Present Phase 3 IMPALA-2 Trial Results of Molgramostim for aPAP at 2024 BTS Winter Meeting

LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical-stage biopharmaceutical firm concentrating on rare respiratory disorders, has announced an encore presentation of findings from the crucial Phase 3 IMPALA-2 trial. The presentation will be showcased at the British Thoracic Society (BTS) Winter Meeting, which is scheduled to occur from November 27-29, 2024, in London, England.

The presentation, titled “Inhaled Molgramostim Improves Pulmonary Gas Exchange and Respiratory Health-Related Quality of Life in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP): Results from IMPALA-2,” will be part of the spoken session “The Famous Five — Emerging clinical trial data” on November 29, 2024, from 8:30 am to 9:50 am GMT. This session will take place at the QEII Centre in London, specifically in the St. James Room on the 4th floor. Dr. Cormac McCarthy, an Associate Professor of Medicine at University College Dublin and a Consultant Respiratory Physician at St. Vincent’s University Hospital in Dublin, Ireland, will deliver the presentation. After the session, the presentation slides will be accessible on the Articles & Publications page of Savara’s corporate website.

Autoimmune Pulmonary Alveolar Proteinosis (aPAP) is a rare lung disease characterized by the excessive accumulation of surfactant within the alveoli, or air sacs, of the lungs. Surfactant, composed of proteins and lipids, is a vital substance that lines the alveoli to prevent them from collapsing. Normally, alveolar macrophages, stimulated by granulocyte-macrophage colony-stimulating factor (GM-CSF), clear and digest excess surfactant. However, in aPAP, antibodies neutralize GM-CSF, disabling the macrophages from effectively clearing the surfactant. This leads to a build-up of surfactant in the alveoli, impairing gas exchange and causing symptoms such as shortness of breath, cough, and fatigue. Patients may also suffer from fever, chest pain, or hemoptysis (coughing up blood) if a secondary lung infection develops. Long-term implications of the disease can include severe complications like lung fibrosis and the potential necessity for a lung transplant.

Savara Inc. is dedicated to addressing rare respiratory conditions. Their leading program involves molgramostim inhalation solution, a recombinant human GM-CSF currently in Phase 3 trials for the treatment of aPAP. Molgramostim is administered via the investigational eFlow® Nebulizer System from PARI Pharma GmbH, which is specifically designed for the inhalation of large molecules. The management at Savara has extensive expertise in rare respiratory diseases and pulmonary medicine, focusing on identifying unmet medical needs and progressing product candidates toward approval and commercialization.